標(biāo)題：求購克拉霉素緩釋片USP41標(biāo)準(zhǔn) 詳細(xì)要求： 需求名稱：克拉霉素緩釋片標(biāo)準(zhǔn) 具體要求：USP42 要求時(shí)間：請?jiān)?019年05月15日之前 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會(huì)每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

要求PDF格式，2015年，越詳細(xì)越好   [更多]

求購Rotigotine 《EP9.6》的藥典標(biāo)準(zhǔn)一份   [更多]

一種透明質(zhì)酸凝膠型的敷料，用于淺表皮膚修復(fù)，主要針對痤瘡、面部皮炎、激素依賴性皮炎、嬰幼兒濕疹等皮膚問題的輔助治療。 具體要求： 產(chǎn)品風(fēng)險(xiǎn)分析報(bào)告 產(chǎn)品技術(shù)要求 產(chǎn)品檢驗(yàn)報(bào)告 臨床評價(jià)資料 產(chǎn)品說明書及標(biāo)簽樣稿 與產(chǎn)品研制、生產(chǎn)有關(guān)的質(zhì)量管理體系文件 生產(chǎn)制造信息 符合性聲明等等   [更多]

文獻(xiàn)標(biāo)題： 1："kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Chapman AB1, Devuyst O2, Eckardt KU3, Gansevoort RT4, Harris T5, Horie S6, Kasiske BL7, Odland D8, Pei Y9, Perrone RD10, Pirson Y11, Schrier RW12, Torra R13, Torres VE14, Watnick T15, Wheeler DC16; Conference Participants." 2："Kidney Int. 2015 Oct;88(4):676-83. doi: 10.1038/ki.2015.28. Epub 2015 Mar 4. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report. Eckardt KU1, Alper SL2, Antignac C3,4, Bleyer AJ5, Chauveau D6, Dahan K7, Deltas C8, Hosking A9, Kmoch S10, Rampoldi L11, Wiesener M1, Wolf MT12, Devuyst O13; Kidney Disease: Improving Global Outcomes." 3：alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 1 trials.the lan lancet et oncology. 4：Topical treatment of glaucoma: established and emerging pharmacology 5：Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.   [更多]

求購Rotigotine Transdermal System《USP43-NF38》的藥典標(biāo)準(zhǔn)一份   [更多]

求購Monographs: Medicinal and Pharmaceutical Substances:Rotigotine《BP2020》的藥典標(biāo)準(zhǔn)一份   [更多]

藥品注冊標(biāo)準(zhǔn)JX19990117   [更多]

求購“Oseltamivir phosphate”《 EP9.2 》的藥典標(biāo)準(zhǔn)一份.   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]